The presentation will focus on Vanqua’s development candidate VQ-201, an allosteric small molecule C5aR1 antagonist targeting complement-mediated inflammation associated with peripheral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback